Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.

[1]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[2]  R. Salazar,et al.  Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ying Cheng,et al.  Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Van Cutsem,et al.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Greil,et al.  Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Pittman,et al.  Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLC. , 2012 .

[7]  C. Porta,et al.  Sequential use of sorafenib and sunitinib in advanced renal‐cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases , 2011, BJU international.

[8]  N. Hanna,et al.  Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  D. Kerr,et al.  Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Van Cutsem,et al.  Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Hamm,et al.  A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Neeraj Gupta,et al.  Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Goh,et al.  ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside , 2009, Journal of hematology & oncology.

[14]  W. Scheithauer,et al.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Lenz,et al.  Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  K. Hayashi,et al.  Vascular Endothelial Growth Factor Messenger RNA Expression Level Is Preserved in Liver Metastases Compared with Corresponding Primary Colorectal Cancer , 2006, Clinical Cancer Research.

[19]  K. Glaser,et al.  Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor , 2005, Molecular Cancer Therapeutics.

[20]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[21]  D. Coppola,et al.  Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors , 2004, Oncogene.

[22]  R. Kerbel.  Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Mizumoto,et al.  Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. , 1998, British Journal of Cancer.

[24]  R. Muraoka,et al.  Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. , 1997, Cancer research.

[25]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[26]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[27]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.